Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab
To validate a ‘drug score’ that stratifies patients receiving immunotherapy based on concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial carcinoma (UC). We assessed oncological outcomes according to the drug score in 242 patients with advanced UC treated with p...
Gespeichert in:
| Veröffentlicht in: | Immunotherapy 2023-08, Vol.15 (11), p.827-837 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 837 |
|---|---|
| container_issue | 11 |
| container_start_page | 827 |
| container_title | Immunotherapy |
| container_volume | 15 |
| creator | Taguchi, Satoru Kawai, Taketo Buti, Sebastiano Bersanelli, Melissa Uemura, Yukari Kishitani, Kenjiro Miyakawa, Jimpei Sugimoto, Kazuma Nakamura, Yu Niimi, Fusako Kaneko, Tomoyuki Kamei, Jun Obinata, Daisuke Yamaguchi, Kenya Kakutani, Shigenori Kanazawa, Koichiro Sugihara, Yuriko Tokunaga, Mayuko Akiyama, Yoshiyuki Yamada, Yuta Sato, Yusuke Yamada, Daisuke Enomoto, Yutaka Nishimatsu, Hiroaki Fujimura, Tetsuya Fukuhara, Hiroshi Nakagawa, Tohru Takahashi, Satoru Kume, Haruki |
| description | To validate a ‘drug score’ that stratifies patients receiving immunotherapy based on concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial carcinoma (UC).
We assessed oncological outcomes according to the drug score in 242 patients with advanced UC treated with pembrolizumab.
The drug score classified patients into three risk groups with significantly different survivals. Heterogeneous treatment effect analyses showed that the primary cancer site (bladder UC [BUC] or upper-tract UC [UTUC]) significantly affected the prognostic capability of the drug score; it significantly correlated with survivals in BUC, while there were no such correlations in UTUC.
A drug score was examined in advanced UC treated with pembrolizumab and was validated in BUC but not in UTUC.
Drug treatment for cancer may be weakened by other drugs. We checked whether some kinds of drugs really weakened the effect of drug treatment for cancer. We found that it was true for some kinds of cancer but not for other kinds.
A concomitant drug-based score was validated in advanced urothelial cancer treated with pembrolizumab. It was validated in bladder cancer but not in upper-tract urothelial cancer. |
| doi_str_mv | 10.2217/imt-2023-0028 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2217_imt_2023_0028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37191002</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-1ad465be28726f84b7b843df710c7357a9e9f6be2739cd83aeccb1bee7d168273</originalsourceid><addsrcrecordid>eNp1kEtLxDAQgIMo7rp69Cr5A9Gk6TbtURZfIHhR8SCUSTJ1I30sSarorzdLdW-e5vXNwHyEnAp-nmVCXbgusoxnknGelXtkLtSSM5Xn5f4uly8zchTCO-dFror8kMykEpVIC3Py-gytsxDd0NOhoUCtH9-YhoCWBjN4pK6nYD-gN6kz-iGusXXQUgPeuH7ogEaPENPw08U13WCn_dC677EDfUwOGmgDnvzGBXm6vnpc3bL7h5u71eU9MzKXkQmwebHUmJUqK5oy10qXubSNEtwouVRQYdUUaa5kZWwpAY3RQiMqK4oydReETXeNH0Lw2NQb7zrwX7Xg9dZSnSzVW0v11lLizyZ-M-oO7Y7-05KAagKaMY4eg3GY_q-nKm249Dr-c_wHaHR4bQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab</title><source>MEDLINE</source><source>PubMed Central</source><creator>Taguchi, Satoru ; Kawai, Taketo ; Buti, Sebastiano ; Bersanelli, Melissa ; Uemura, Yukari ; Kishitani, Kenjiro ; Miyakawa, Jimpei ; Sugimoto, Kazuma ; Nakamura, Yu ; Niimi, Fusako ; Kaneko, Tomoyuki ; Kamei, Jun ; Obinata, Daisuke ; Yamaguchi, Kenya ; Kakutani, Shigenori ; Kanazawa, Koichiro ; Sugihara, Yuriko ; Tokunaga, Mayuko ; Akiyama, Yoshiyuki ; Yamada, Yuta ; Sato, Yusuke ; Yamada, Daisuke ; Enomoto, Yutaka ; Nishimatsu, Hiroaki ; Fujimura, Tetsuya ; Fukuhara, Hiroshi ; Nakagawa, Tohru ; Takahashi, Satoru ; Kume, Haruki</creator><creatorcontrib>Taguchi, Satoru ; Kawai, Taketo ; Buti, Sebastiano ; Bersanelli, Melissa ; Uemura, Yukari ; Kishitani, Kenjiro ; Miyakawa, Jimpei ; Sugimoto, Kazuma ; Nakamura, Yu ; Niimi, Fusako ; Kaneko, Tomoyuki ; Kamei, Jun ; Obinata, Daisuke ; Yamaguchi, Kenya ; Kakutani, Shigenori ; Kanazawa, Koichiro ; Sugihara, Yuriko ; Tokunaga, Mayuko ; Akiyama, Yoshiyuki ; Yamada, Yuta ; Sato, Yusuke ; Yamada, Daisuke ; Enomoto, Yutaka ; Nishimatsu, Hiroaki ; Fujimura, Tetsuya ; Fukuhara, Hiroshi ; Nakagawa, Tohru ; Takahashi, Satoru ; Kume, Haruki</creatorcontrib><description>To validate a ‘drug score’ that stratifies patients receiving immunotherapy based on concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial carcinoma (UC).
We assessed oncological outcomes according to the drug score in 242 patients with advanced UC treated with pembrolizumab.
The drug score classified patients into three risk groups with significantly different survivals. Heterogeneous treatment effect analyses showed that the primary cancer site (bladder UC [BUC] or upper-tract UC [UTUC]) significantly affected the prognostic capability of the drug score; it significantly correlated with survivals in BUC, while there were no such correlations in UTUC.
A drug score was examined in advanced UC treated with pembrolizumab and was validated in BUC but not in UTUC.
Drug treatment for cancer may be weakened by other drugs. We checked whether some kinds of drugs really weakened the effect of drug treatment for cancer. We found that it was true for some kinds of cancer but not for other kinds.
A concomitant drug-based score was validated in advanced urothelial cancer treated with pembrolizumab. It was validated in bladder cancer but not in upper-tract urothelial cancer.</description><identifier>ISSN: 1750-743X</identifier><identifier>EISSN: 1750-7448</identifier><identifier>DOI: 10.2217/imt-2023-0028</identifier><identifier>PMID: 37191002</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>antibiotic ; Antibodies, Monoclonal, Humanized - therapeutic use ; Carcinoma, Transitional Cell - drug therapy ; Carcinoma, Transitional Cell - pathology ; corticosteroid ; gut microbiome ; heterogeneity of treatment effect ; Humans ; immune checkpoint inhibitor ; pembrolizumab ; Prognosis ; proton pump inhibitor ; Retrospective Studies ; Urinary Bladder Neoplasms - drug therapy ; urothelial carcinoma</subject><ispartof>Immunotherapy, 2023-08, Vol.15 (11), p.827-837</ispartof><rights>2023 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-1ad465be28726f84b7b843df710c7357a9e9f6be2739cd83aeccb1bee7d168273</citedby><cites>FETCH-LOGICAL-c343t-1ad465be28726f84b7b843df710c7357a9e9f6be2739cd83aeccb1bee7d168273</cites><orcidid>0000-0002-5762-7563 ; 0000-0003-1439-5640 ; 0000-0002-5404-600X ; 0000-0003-0876-0226 ; 0000-0002-3013-7775 ; 0000-0002-1291-4294 ; 0000-0003-4041-7241 ; 0000-0002-0069-7392 ; 0000-0002-6527-6281 ; 0000-0002-7279-2874 ; 0000-0002-9698-4301 ; 0000-0002-2296-6653</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37191002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taguchi, Satoru</creatorcontrib><creatorcontrib>Kawai, Taketo</creatorcontrib><creatorcontrib>Buti, Sebastiano</creatorcontrib><creatorcontrib>Bersanelli, Melissa</creatorcontrib><creatorcontrib>Uemura, Yukari</creatorcontrib><creatorcontrib>Kishitani, Kenjiro</creatorcontrib><creatorcontrib>Miyakawa, Jimpei</creatorcontrib><creatorcontrib>Sugimoto, Kazuma</creatorcontrib><creatorcontrib>Nakamura, Yu</creatorcontrib><creatorcontrib>Niimi, Fusako</creatorcontrib><creatorcontrib>Kaneko, Tomoyuki</creatorcontrib><creatorcontrib>Kamei, Jun</creatorcontrib><creatorcontrib>Obinata, Daisuke</creatorcontrib><creatorcontrib>Yamaguchi, Kenya</creatorcontrib><creatorcontrib>Kakutani, Shigenori</creatorcontrib><creatorcontrib>Kanazawa, Koichiro</creatorcontrib><creatorcontrib>Sugihara, Yuriko</creatorcontrib><creatorcontrib>Tokunaga, Mayuko</creatorcontrib><creatorcontrib>Akiyama, Yoshiyuki</creatorcontrib><creatorcontrib>Yamada, Yuta</creatorcontrib><creatorcontrib>Sato, Yusuke</creatorcontrib><creatorcontrib>Yamada, Daisuke</creatorcontrib><creatorcontrib>Enomoto, Yutaka</creatorcontrib><creatorcontrib>Nishimatsu, Hiroaki</creatorcontrib><creatorcontrib>Fujimura, Tetsuya</creatorcontrib><creatorcontrib>Fukuhara, Hiroshi</creatorcontrib><creatorcontrib>Nakagawa, Tohru</creatorcontrib><creatorcontrib>Takahashi, Satoru</creatorcontrib><creatorcontrib>Kume, Haruki</creatorcontrib><title>Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab</title><title>Immunotherapy</title><addtitle>Immunotherapy</addtitle><description>To validate a ‘drug score’ that stratifies patients receiving immunotherapy based on concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial carcinoma (UC).
We assessed oncological outcomes according to the drug score in 242 patients with advanced UC treated with pembrolizumab.
The drug score classified patients into three risk groups with significantly different survivals. Heterogeneous treatment effect analyses showed that the primary cancer site (bladder UC [BUC] or upper-tract UC [UTUC]) significantly affected the prognostic capability of the drug score; it significantly correlated with survivals in BUC, while there were no such correlations in UTUC.
A drug score was examined in advanced UC treated with pembrolizumab and was validated in BUC but not in UTUC.
Drug treatment for cancer may be weakened by other drugs. We checked whether some kinds of drugs really weakened the effect of drug treatment for cancer. We found that it was true for some kinds of cancer but not for other kinds.
A concomitant drug-based score was validated in advanced urothelial cancer treated with pembrolizumab. It was validated in bladder cancer but not in upper-tract urothelial cancer.</description><subject>antibiotic</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Carcinoma, Transitional Cell - drug therapy</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>corticosteroid</subject><subject>gut microbiome</subject><subject>heterogeneity of treatment effect</subject><subject>Humans</subject><subject>immune checkpoint inhibitor</subject><subject>pembrolizumab</subject><subject>Prognosis</subject><subject>proton pump inhibitor</subject><subject>Retrospective Studies</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><subject>urothelial carcinoma</subject><issn>1750-743X</issn><issn>1750-7448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtLxDAQgIMo7rp69Cr5A9Gk6TbtURZfIHhR8SCUSTJ1I30sSarorzdLdW-e5vXNwHyEnAp-nmVCXbgusoxnknGelXtkLtSSM5Xn5f4uly8zchTCO-dFror8kMykEpVIC3Py-gytsxDd0NOhoUCtH9-YhoCWBjN4pK6nYD-gN6kz-iGusXXQUgPeuH7ogEaPENPw08U13WCn_dC677EDfUwOGmgDnvzGBXm6vnpc3bL7h5u71eU9MzKXkQmwebHUmJUqK5oy10qXubSNEtwouVRQYdUUaa5kZWwpAY3RQiMqK4oydReETXeNH0Lw2NQb7zrwX7Xg9dZSnSzVW0v11lLizyZ-M-oO7Y7-05KAagKaMY4eg3GY_q-nKm249Dr-c_wHaHR4bQ</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Taguchi, Satoru</creator><creator>Kawai, Taketo</creator><creator>Buti, Sebastiano</creator><creator>Bersanelli, Melissa</creator><creator>Uemura, Yukari</creator><creator>Kishitani, Kenjiro</creator><creator>Miyakawa, Jimpei</creator><creator>Sugimoto, Kazuma</creator><creator>Nakamura, Yu</creator><creator>Niimi, Fusako</creator><creator>Kaneko, Tomoyuki</creator><creator>Kamei, Jun</creator><creator>Obinata, Daisuke</creator><creator>Yamaguchi, Kenya</creator><creator>Kakutani, Shigenori</creator><creator>Kanazawa, Koichiro</creator><creator>Sugihara, Yuriko</creator><creator>Tokunaga, Mayuko</creator><creator>Akiyama, Yoshiyuki</creator><creator>Yamada, Yuta</creator><creator>Sato, Yusuke</creator><creator>Yamada, Daisuke</creator><creator>Enomoto, Yutaka</creator><creator>Nishimatsu, Hiroaki</creator><creator>Fujimura, Tetsuya</creator><creator>Fukuhara, Hiroshi</creator><creator>Nakagawa, Tohru</creator><creator>Takahashi, Satoru</creator><creator>Kume, Haruki</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-5762-7563</orcidid><orcidid>https://orcid.org/0000-0003-1439-5640</orcidid><orcidid>https://orcid.org/0000-0002-5404-600X</orcidid><orcidid>https://orcid.org/0000-0003-0876-0226</orcidid><orcidid>https://orcid.org/0000-0002-3013-7775</orcidid><orcidid>https://orcid.org/0000-0002-1291-4294</orcidid><orcidid>https://orcid.org/0000-0003-4041-7241</orcidid><orcidid>https://orcid.org/0000-0002-0069-7392</orcidid><orcidid>https://orcid.org/0000-0002-6527-6281</orcidid><orcidid>https://orcid.org/0000-0002-7279-2874</orcidid><orcidid>https://orcid.org/0000-0002-9698-4301</orcidid><orcidid>https://orcid.org/0000-0002-2296-6653</orcidid></search><sort><creationdate>20230801</creationdate><title>Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab</title><author>Taguchi, Satoru ; Kawai, Taketo ; Buti, Sebastiano ; Bersanelli, Melissa ; Uemura, Yukari ; Kishitani, Kenjiro ; Miyakawa, Jimpei ; Sugimoto, Kazuma ; Nakamura, Yu ; Niimi, Fusako ; Kaneko, Tomoyuki ; Kamei, Jun ; Obinata, Daisuke ; Yamaguchi, Kenya ; Kakutani, Shigenori ; Kanazawa, Koichiro ; Sugihara, Yuriko ; Tokunaga, Mayuko ; Akiyama, Yoshiyuki ; Yamada, Yuta ; Sato, Yusuke ; Yamada, Daisuke ; Enomoto, Yutaka ; Nishimatsu, Hiroaki ; Fujimura, Tetsuya ; Fukuhara, Hiroshi ; Nakagawa, Tohru ; Takahashi, Satoru ; Kume, Haruki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-1ad465be28726f84b7b843df710c7357a9e9f6be2739cd83aeccb1bee7d168273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>antibiotic</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Carcinoma, Transitional Cell - drug therapy</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>corticosteroid</topic><topic>gut microbiome</topic><topic>heterogeneity of treatment effect</topic><topic>Humans</topic><topic>immune checkpoint inhibitor</topic><topic>pembrolizumab</topic><topic>Prognosis</topic><topic>proton pump inhibitor</topic><topic>Retrospective Studies</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><topic>urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taguchi, Satoru</creatorcontrib><creatorcontrib>Kawai, Taketo</creatorcontrib><creatorcontrib>Buti, Sebastiano</creatorcontrib><creatorcontrib>Bersanelli, Melissa</creatorcontrib><creatorcontrib>Uemura, Yukari</creatorcontrib><creatorcontrib>Kishitani, Kenjiro</creatorcontrib><creatorcontrib>Miyakawa, Jimpei</creatorcontrib><creatorcontrib>Sugimoto, Kazuma</creatorcontrib><creatorcontrib>Nakamura, Yu</creatorcontrib><creatorcontrib>Niimi, Fusako</creatorcontrib><creatorcontrib>Kaneko, Tomoyuki</creatorcontrib><creatorcontrib>Kamei, Jun</creatorcontrib><creatorcontrib>Obinata, Daisuke</creatorcontrib><creatorcontrib>Yamaguchi, Kenya</creatorcontrib><creatorcontrib>Kakutani, Shigenori</creatorcontrib><creatorcontrib>Kanazawa, Koichiro</creatorcontrib><creatorcontrib>Sugihara, Yuriko</creatorcontrib><creatorcontrib>Tokunaga, Mayuko</creatorcontrib><creatorcontrib>Akiyama, Yoshiyuki</creatorcontrib><creatorcontrib>Yamada, Yuta</creatorcontrib><creatorcontrib>Sato, Yusuke</creatorcontrib><creatorcontrib>Yamada, Daisuke</creatorcontrib><creatorcontrib>Enomoto, Yutaka</creatorcontrib><creatorcontrib>Nishimatsu, Hiroaki</creatorcontrib><creatorcontrib>Fujimura, Tetsuya</creatorcontrib><creatorcontrib>Fukuhara, Hiroshi</creatorcontrib><creatorcontrib>Nakagawa, Tohru</creatorcontrib><creatorcontrib>Takahashi, Satoru</creatorcontrib><creatorcontrib>Kume, Haruki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taguchi, Satoru</au><au>Kawai, Taketo</au><au>Buti, Sebastiano</au><au>Bersanelli, Melissa</au><au>Uemura, Yukari</au><au>Kishitani, Kenjiro</au><au>Miyakawa, Jimpei</au><au>Sugimoto, Kazuma</au><au>Nakamura, Yu</au><au>Niimi, Fusako</au><au>Kaneko, Tomoyuki</au><au>Kamei, Jun</au><au>Obinata, Daisuke</au><au>Yamaguchi, Kenya</au><au>Kakutani, Shigenori</au><au>Kanazawa, Koichiro</au><au>Sugihara, Yuriko</au><au>Tokunaga, Mayuko</au><au>Akiyama, Yoshiyuki</au><au>Yamada, Yuta</au><au>Sato, Yusuke</au><au>Yamada, Daisuke</au><au>Enomoto, Yutaka</au><au>Nishimatsu, Hiroaki</au><au>Fujimura, Tetsuya</au><au>Fukuhara, Hiroshi</au><au>Nakagawa, Tohru</au><au>Takahashi, Satoru</au><au>Kume, Haruki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab</atitle><jtitle>Immunotherapy</jtitle><addtitle>Immunotherapy</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>15</volume><issue>11</issue><spage>827</spage><epage>837</epage><pages>827-837</pages><issn>1750-743X</issn><eissn>1750-7448</eissn><abstract>To validate a ‘drug score’ that stratifies patients receiving immunotherapy based on concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial carcinoma (UC).
We assessed oncological outcomes according to the drug score in 242 patients with advanced UC treated with pembrolizumab.
The drug score classified patients into three risk groups with significantly different survivals. Heterogeneous treatment effect analyses showed that the primary cancer site (bladder UC [BUC] or upper-tract UC [UTUC]) significantly affected the prognostic capability of the drug score; it significantly correlated with survivals in BUC, while there were no such correlations in UTUC.
A drug score was examined in advanced UC treated with pembrolizumab and was validated in BUC but not in UTUC.
Drug treatment for cancer may be weakened by other drugs. We checked whether some kinds of drugs really weakened the effect of drug treatment for cancer. We found that it was true for some kinds of cancer but not for other kinds.
A concomitant drug-based score was validated in advanced urothelial cancer treated with pembrolizumab. It was validated in bladder cancer but not in upper-tract urothelial cancer.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>37191002</pmid><doi>10.2217/imt-2023-0028</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-5762-7563</orcidid><orcidid>https://orcid.org/0000-0003-1439-5640</orcidid><orcidid>https://orcid.org/0000-0002-5404-600X</orcidid><orcidid>https://orcid.org/0000-0003-0876-0226</orcidid><orcidid>https://orcid.org/0000-0002-3013-7775</orcidid><orcidid>https://orcid.org/0000-0002-1291-4294</orcidid><orcidid>https://orcid.org/0000-0003-4041-7241</orcidid><orcidid>https://orcid.org/0000-0002-0069-7392</orcidid><orcidid>https://orcid.org/0000-0002-6527-6281</orcidid><orcidid>https://orcid.org/0000-0002-7279-2874</orcidid><orcidid>https://orcid.org/0000-0002-9698-4301</orcidid><orcidid>https://orcid.org/0000-0002-2296-6653</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1750-743X |
| ispartof | Immunotherapy, 2023-08, Vol.15 (11), p.827-837 |
| issn | 1750-743X 1750-7448 |
| language | eng |
| recordid | cdi_crossref_primary_10_2217_imt_2023_0028 |
| source | MEDLINE; PubMed Central |
| subjects | antibiotic Antibodies, Monoclonal, Humanized - therapeutic use Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - pathology corticosteroid gut microbiome heterogeneity of treatment effect Humans immune checkpoint inhibitor pembrolizumab Prognosis proton pump inhibitor Retrospective Studies Urinary Bladder Neoplasms - drug therapy urothelial carcinoma |
| title | Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T07%3A41%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validation%20of%20a%20drug-based%20score%20in%20advanced%20urothelial%20carcinoma%20treated%20with%20pembrolizumab&rft.jtitle=Immunotherapy&rft.au=Taguchi,%20Satoru&rft.date=2023-08-01&rft.volume=15&rft.issue=11&rft.spage=827&rft.epage=837&rft.pages=827-837&rft.issn=1750-743X&rft.eissn=1750-7448&rft_id=info:doi/10.2217/imt-2023-0028&rft_dat=%3Cpubmed_cross%3E37191002%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37191002&rfr_iscdi=true |